Slow and fast non-Hodgkin lymphomas: follicular, marginal zone, mantle cell, DLBCL, Burkitt
- Look-alikes compared
Some lymphomas grow for years without harm; others double in days. Knowing which one is in front of you decides whether to watch or treat today.
What it is
B-cell non-Hodgkin lymphomas are grouped by behaviour. Indolent lymphomas (follicular, marginal zone including MALT) grow slowly, are often widespread at diagnosis and usually return after treatment, yet patients live for many years. Aggressive lymphomas (diffuse large B-cell lymphoma, DLBCL, and Burkitt lymphoma) grow fast, cause symptoms within weeks and are curable with chemoimmunotherapy in many patients. Mantle cell lymphoma sits between: it usually behaves aggressively but, like the indolent types, is rarely cured.
The difference in one line
- Follicular: the commonest indolent lymphoma; t(14;18) IGH::BCL2; CD10 and BCL2 positive in the follicles; painless nodes that may wax and wane.
- Marginal zone and MALT: chronic antigen drive; gastric MALT with H. pylori, salivary MALT with Sjögren disease, thyroid with Hashimoto thyroiditis, splenic marginal zone with hepatitis C.
- Mantle cell: CD5 positive like CLL but CD23 negative, cyclin D1 from t(11;14) IGH::CCND1, SOX11; older men, big spleen, marrow and gut polyps.
- DLBCL: the commonest lymphoma overall; a fast-growing node or extranodal mass with B symptoms and a high LDH; MYC plus BCL2 rearrangement ('double hit') behaves worse.
- Burkitt: medium cells, almost every cell dividing, a 'starry sky' of macrophages eating dead cells; MYC t(8;14); endemic (jaw, EBV, malaria regions), sporadic (abdomen) and immunodeficiency (HIV) forms.
- Transformation: an indolent lymphoma that suddenly grows, raises the LDH or causes B symptoms may have turned into DLBCL and needs a new biopsy.
Five B-cell lymphomas side by side
| Feature | Follicular | Marginal zone / MALT | Mantle cell | DLBCL | Burkitt |
|---|---|---|---|---|---|
| Behaviour | Indolent, relapsing | Indolent, often localised | Usually aggressive, rarely cured | Aggressive, often curable | Very aggressive, curable |
| Markers | CD10+, BCL2+, BCL6+ | CD5−, CD10− | CD5+, CD23−, cyclin D1+, SOX11+ | CD20+ large cells; GCB or ABC type | CD10+, BCL2−, Ki-67 nearly 100% |
| Genetics | t(14;18) IGH::BCL2 | t(11;18) in some gastric MALT | t(11;14) IGH::CCND1 | Varied; MYC with BCL2 = double hit | t(8;14) MYC |
| Typical patient | Older adult, painless widespread nodes | Stomach pain with H. pylori, or a salivary or thyroid mass | Older man, nodes, big spleen, gut polyps | Adult with a fast-growing mass, B symptoms | Child or young adult, abdominal or jaw mass, HIV |
| Treatment principle | Watch if low burden; anti-CD20 based when needed | Treat the antigen (H. pylori) first; radiotherapy or anti-CD20 | Chemoimmunotherapy, BTK inhibitors, transplant in fit patients | Anti-CD20 plus anthracycline-based chemotherapy | Short intensive chemotherapy with CNS prophylaxis; prevent tumour lysis |
In clinical practice
- Early gastric MALT lymphoma with H. pylori can regress with eradication therapy alone; t(11;18) predicts that it will not.
- A patient with low-burden follicular lymphoma and no symptoms gains nothing in survival from immediate treatment; watchful waiting is an active, evidence-based choice.
- Burkitt lymphoma can double in about a day: biopsy, staging and treatment start within days, with tumour lysis prevention from the first hour.
- Before any anti-CD20 antibody, test for hepatitis B: reactivation can cause fatal hepatitis.
How it is confirmed
- Excision or core biopsy with immunohistochemistry (CD20, CD5, CD10, CD23, BCL2, BCL6, cyclin D1, Ki-67) and FISH for MYC, BCL2 and BCL6 in aggressive lymphoma.
- Gastric MALT: test for H. pylori and t(11;18).
- Staging with PET-CT, LDH, full count, HIV, hepatitis B and C serology.
- Sudden growth, rising LDH or B symptoms in an indolent lymphoma: re-biopsy the most active site on PET.
Common traps
- Calling a CD5-positive lymphoma CLL without checking CD23 and cyclin D1: mantle cell lymphoma is CD5 positive too.
- Thinking a slow lymphoma must be easy to cure: follicular lymphoma responds but usually returns, while DLBCL is often cured.
- Missing what BCL2 in a germinal centre means: it signals follicular lymphoma; reactive follicles are BCL2 negative.
- Starting chemotherapy for gastric MALT before treating H. pylori: H. pylori is treated first.
- Forgetting hepatitis B screening before anti-CD20 therapy: the screening comes before treatment starts.
Test yourself
Think of the answer, then tap the question to see it.
Why is follicular lymphoma, which grows slowly, usually harder to cure than DLBCL?
Its cells survive by blocking apoptosis (BCL2) rather than dividing fast, so chemotherapy, which targets dividing cells, rarely removes all of them; DLBCL cells divide rapidly and are more chemosensitive.
A CD5-positive small B-cell lymphoma is CD23 negative and cyclin D1 positive. Which lymphoma is it?
Mantle cell lymphoma, from t(11;14) IGH::CCND1; CLL is CD5 positive but CD23 positive and cyclin D1 negative.
What is the first treatment for early gastric MALT lymphoma with H. pylori, and which finding predicts failure?
H. pylori eradication; the t(11;18) translocation predicts that the lymphoma will not regress with eradication alone.
A patient with follicular lymphoma for six years develops a rapidly growing node and a high LDH. What should happen next?
Suspect transformation to DLBCL and biopsy the most active site, guided by PET-CT, because treatment changes to that of an aggressive lymphoma.
Elsewhere in DurgiPedia
- Follicular lymphoma
- Marginal zone lymphomas
- Mantle cell lymphoma: cyclin D1, CD5 and lymphomatous polyposis
- Diffuse large B-cell lymphoma
- Burkitt lymphoma
- Gastrointestinal lymphoma
- Extrafollicular and germinal-centre B-cell responses
- Mucosa-associated lymphoid tissue (tonsils, Peyer patches)
Connections
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Follicular Lymphoma (StatPearls (NCBI Bookshelf), 2024); Mantle Cell Lymphoma (StatPearls (NCBI Bookshelf), 2023); Diffuse Large B-Cell Lymphoma (StatPearls (NCBI Bookshelf), 2023); Burkitt lymphoma: MedlinePlus Medical Encyclopedia (MedlinePlus, US National Library of Medicine, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
